Sanket Koul

BorderPlus to send 1,000 Indian nurses to Gulf Cooperation Council by FY27

GCC healthcare ecosystem projected to require over 50,000 additional nurses by 2027, says BorderPlus CEO

IITs' push to broaden job profiles pays dividends with diverse offers

Hedge funds and trading firms outpace start-ups in placement drives

Birla Estates partners Sikka Group to co-develop ₹1,600 cr Noida project

Birla Estates has tied up with Sikka Group to co-develop a ₹1,600-crore Greater Noida housing project, leveraging new revival policies that allow creditworthy developers to take over stalled projects

DRL semaglutide ruling may set precedent for generic makers: Experts

Ruling enables production for non-patented markets but bars India sales till 2026; experts say it may shape future drug access cases

WHO issues first guidelines backing GLP-1 drugs for obesity management

WHO has issued its first guidelines recommending GLP-1 drugs for long-term obesity treatment in adults, while stressing equitable access, health system readiness and lifestyle support

Metropolis launches GLP-1 monitoring test packages, targets obesity market

Metropolis Healthcare has rolled out three TruHealth GLP-1 test packages for patients preparing for or undergoing obesity treatment, as diagnostics firms move to tap the fast-growing segment

IITs see strong recruiter rush on Day 1 as top firms roll out big offers

Day 1 of IIT placements saw a surge of top recruiters, with NVIDIA, Amazon, Zomato, Google and Flipkart among those offering high-value roles, as more students opted for final placements over PPOs

PMJAY for 70+ logged 700k treatments worth ₹1,471 crore in first year

Centre to ramp up awareness, with 15% of the 60 million senior citizen target covered, even as experts flag budgetary issues, slow pace

CDSCO committee considers avoiding high-risk solvents in kids' oral drugs

Move follows reports of deaths from contaminated cough syrups in Chhindwara

Mount K Kapital raises 2nd realty fund worth ₹4K cr, to expand beyond MMR

The seven-year credit fund will back 10-15 projects across major cities, building on the firm's first Rs 790 crore vehicle

HDFC Capital, Hero Realty set up ₹1K cr platform for mid-income housing

HDFC Capital has tied up with Hero Realty to build a Rs 1,000 crore mid-income housing platform aimed at accelerating development across Tier 1 and Tier 2 cities

CDSCO panel seeks uniform enforcement of drug standards across states

The DCC has asked the Centre to address gaps in drug-standard enforcement, write to states on non-uniform norms and improve testing and regulatory infrastructure highlighted under the SHRESTH index

Affordable homes lose investor appeal as luxury delivers higher returns

With luxury home prices rising faster than affordable units and branded developers driving demand in prime locations, investors are shifting towards premium and luxury housing

Eris Lifesciences to acquire 30% stake in Swiss Parenterals for ₹423 cr

Eris Lifesciences will purchase the final 30% stake in Swiss Parenterals through a Rs 423-crore share swap, aiming for full consolidation, greater cost efficiency and strengthened strategic control

Central Park to invest ₹2,000 cr in luxury residential project in Gurugram

People in the know told Business Standard that the ticket prices for the studio apartments would range between Rs 3 crore and Rs 5 crore, while that for 3 and 4 BHK apartments would be ₹11 cr, ₹15 cr

Labour codes: Real estate expects up to 10% spike in baseline labour cost

Developers expect short-term cost and timeline pressures, but say unified labour laws will bring predictability, better compliance and steadier workforce availability

ATS HomeKraft provides ₹1,250 cr exit to HDFC Capital's HCARE-2 fund

The ATS group developer cleared dues to HCARE-2 entirely through project cash flows, highlighting strong demand and healthier balance sheets in mid-income housing

MNC drugmakers push for 10-year exclusivity period for trial data

First entities' data filed for novel drugs needs protection: OPPI

Drug regulator mandates CDSCO licensing on medical device procurement

The regulator told states not to demand USFDA or EU approvals in tenders after complaints that Indian-made devices were being sidelined

SC's green clearance ruling recall could push ahead stalled projects

Move to give relief to thousands of homebuyers and developers